后来罗氏研发的两类HER2受体靶向药物Perjeta （帕妥珠单抗）和Kadcyla（曲妥珠单抗）进一步提高了患者存活率。
基于62个网页-相关网页
Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.
NPR: FDA Approves New Targeted Breast Cancer Drug
Now those studies are complete and today t he drug has been approved, with the name Kadcyla.
FORBES: A Triumph In Breast Cancer -- And Another Expensive Drug
Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.
应用推荐
模块上移
模块下移
不移动